Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Atomoxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 9/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 14/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 4/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 2/20 | 1.00 |
| ▸ | HTR2A | P28223 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HRH1 | P35367 | 2/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 2/20 | 1.00 |
| ▸ | DRD3 | P35462 | 2/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | KLF10 | Q13118 | 2/20 | 1.00 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atomoxetine SCHEMBL34268 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL5783906 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL341802 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29440242 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL12047445 | 1.00 | SLC6A4 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL1560986 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL29528186 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL2206798 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL649168 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 | |
| Atomoxetine SCHEMBL122111 | 0.98 | SLC6A2 (1.00) | SLC6A4SLC6A2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485754-B2 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. (CA) | 2009-02-03 | — | — | US | claimed |
| WO-2007006132-A1 | AN EFFICIENT METHOD FOR PREPARING 3-ARYLOXY-3- ARYLPROPYLAMINES AND THEIR OPTICAL STEREOISOMERS | APOTEX PHARMACHEM INC. (CA) | 2007-01-18 | — | — | WO | claimed |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. | 2007-01-11 | — | — | US | claimed |
| EP-2124912-B1 | ALPHA-2B ADRENERGIC RECEPTOR AGONIST AND SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITOR COMPOSITIONS FOR TREATING CHRONIC PAIN | ALLERGAN INC (US) | 2014-12-03 | — | — | EP | disclosed |
| CN-102321066-B | Method for producing aryl-aminopropanols | SALTIGO GMBH | 2014-07-23 | — | — | CN | disclosed |
| EP-2348120-B1 | Enzymatic reduction of 1-phenylpropanone and derivatives thereof | Universität Wien (AT) | 2014-06-11 | — | — | EP | disclosed |
| US-8367868-B2 | Process for the synthesis of aryloxypropylamine and heteroaryloxypropylamine | ARCHIMICA S.R.L. (IT) | 2013-02-05 | — | — | US | disclosed |
| US-8367868-B2 | Process for the synthesis of aryloxypropylamine and heteroaryloxypropylamine | ARCHIMICA S.R.L. (IT) | 2013-02-05 | — | — | US | disclosed |
| EP-2348120-A1 | Enzymatic reduction of 1-phenylpropanone and derivatives thereof | Universität Wien (AT) | 2011-07-27 | — | — | EP | disclosed |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | AUSPEX PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | APOTEX PHARMACHEM INC. | 2007-01-11 | — | — | US | disclosed |
| US-20060211772-A1 | Processes for the preparation of atomoxetine hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1687254-A2 | PROCESS FOR THE OPTICAL RESOLUTION AND RECYCLING OF TOMOXETINE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2006-08-09 | — | — | EP | disclosed |
| EP-1673335-A2 | PROCESS FOR THE PREPARATION OF ATOMOXETINE HYDROCHLORIDE | Teva Pharmaceutical Fine Chemicals S.R.L. (IT) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006004976-A2 | PROCESS FOR THE PREPARATION OF ATOMOXETINE HYDROCHLORIDE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-01-12 | — | — | WO | disclosed |
| US-20060009530-A1 | Process for the optical resolution and recycling of tomoxetine | TEVA PHARMACEUTICALS USA, INC. | 2006-01-12 | — | — | US | disclosed |
| WO-2006004977-A2 | PROCESS FOR THE OPTICAL RESOLUTION AND RECYCLING OF TOMOXETINE | TEVA PHARMACEUTICAL FINE CHEMICALS S.R.L. (IT) | 2006-01-12 | — | — | WO | disclosed |
| US-20060009489-A1 | Process for the preparation of atomoxetine hydrochloride | TEVA PHARMACEUTICALS USA, INC. | 2006-01-12 | — | — | US | disclosed |
| CN-1445224-A | Process for preparing arylaminopropanols | BAYER AG (DE) | 2003-10-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060009489-A1 | Process for the preparation of atomoxetine hydrochloride | SLC6A4, HTR5A, SLC6A3 | SLC6A2 4/4885SLC6A4 1/4885CYP1A2 141/4885 |
| US-20060009530-A1 | Process for the optical resolution and recycling of tomoxetine | SLC6A4, SLC6A3, SLC6A2 | SLC6A2 3/4885SLC6A4 1/4885CYP1A2 144/4885 |
| US-20110136914-A1 | SUBSTITUTED ARYLOXYPROPYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY | SLC6A4, HTR4, GPR34 | SLC6A2 5/4885SLC6A4 1/4885CYP1A2 1159/4885 |
| US-20060211772-A1 | Processes for the preparation of atomoxetine hydrochloride | HTR5A, SLC6A4, HTR4 | SLC6A2 5/4885SLC6A4 2/4885CYP1A2 129/4885 |
| US-20070010678-A1 | Efficient method for preparing 3-aryloxy-3-arylpropylamines and their optical stereoisomers | SLC6A4, HTR3A, TPH2 | SLC6A2 13/4885SLC6A4 1/4885CYP1A2 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.